Reading CTKB? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CTKB free→Reading CTKB? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CTKB free→NASDAQHealth CareMedical DevicesSnapshot 2026-06-15
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is weak, and the company was unprofitable over the past year, so its earnings quality can't be assessed. Management's recent track record has been steady, but risk is elevated, and the sector backdrop is a headwind. Peer multiples imply a price about 45% above where it trades (it looks cheap on this basis); the read is cheap, value-trap risk, as it trades below peer multiples, but recent financials are weak. If CTKB cuts guidance on the next call, that's a meaningful negative. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 2 valuation methods, at three horizons. Current price $3.93. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $3.93 CTKB trades at 2× p/s, below its 3× p/s peer median. Our $7.26 fair value sits above the price; medium confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 46% below a flat-multiple fair value, below our forecast of about 12%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 55% of the time over the next year (vs 54% for the rest of the cohort, n=2391).
Over the trailing year it converted 0.10x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, long-term interest rates, Fed net liquidity, real (inflation-adjusted) rates.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.04 → $-0.01 (+75.0% / 30d). 0 raised, 1 cut, 1 covering analysts.
0 upgrades, 0 downgrades / 30d. 50% of analysts rate Buy.
0 positive, 0 negative / 30d.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$162.
How much price usually moves either way.
On a bad day, this stock has moved -$577.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $4,294.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Cytek aims for 2026 revenue of $205M to $212M. Confirmation shows growth momentum.
Confirms:Q2 revenue guidance remains within the range of $205M to $212M.
Disproves:Q2 revenue guidance revised below $205M.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for CTKB yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 27, 2026, Philippe Busque, Ph.D. submitted his resignation from his position as the Senior Vice President, Global Sales and Services of Cytek Biosciences, Inc. (the “Company”), effective as of June 5, 2026, to pursue another career opportunity. Dr. Busque’s resignation is not due to any disagreement with the Company’s operations, policies or…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
Trailing four: 2021-Q3, 2022-Q1, 2022-Q2, 2022-Q3
A side-by-side read on sector standing, valuation, and risk versus Health Care Equipment.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
CTKB Cytek Biosciences, Inc. | Below typical Show detailsSector percentile: 21 of 100 | inexpensive | elevated |
ABT Abbott Laboratories | Above typical Show detailsSector percentile: 94 of 100 | fair | moderate |
ISRG Intuitive Surgical | Above typical Show detailsSector percentile: 94 of 100 | expensive | moderate |
SYK Stryker Corporation | Above typical Show detailsSector percentile: 71 of 100 | fair | moderate |
MDT Medtronic | Above typical Show detailsSector percentile: 89 of 100 | fair | moderate |
1 material management or governance event in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Cytek aims to meet its 2026 revenue guidance range of $205 million to $212 million.
Cytek is focused on improving its operating income through cost management and efficiency.
Cytek aims to increase its gross profit through strategic initiatives and cost management.
Why it matters: The earnings report will show if revenue growth is slowing. This is key for future performance.
Confirms:Earnings report shows revenue growth below the median for the sector.
Disproves:Earnings report shows revenue growth above the median for the sector.
Why it matters: A drop in sector revenue growth could signal broader challenges for Cytek. It may affect market confidence.
Confirms:Sector revenue growth reported below its median.
Disproves:Sector revenue growth remains above its median.
Why it matters: Meeting this target would indicate progress toward the full-year revenue guidance of $205M-$212M.
Confirms:Q2 2026 revenue reported at or above $51.3 million.
Disproves:Q2 2026 revenue reported below $48.5 million.
Why it matters: Better operating income matters. It shows that costs are managed better.
Confirms:Operating income is better than the $18.5 million loss in Q1.
Disproves:Operating income gets worse, showing a loss bigger than $18.5 million.
Why it matters: The Global Sales and Services leader leaving may hurt sales.
Confirms:Sales stay stable or improve even with the leadership change.
Disproves:Sales drop a lot after the executive leaves.
Why it matters: Growth in the installed base drives higher demand for service and reagent revenue.
Confirms:Installed base reported at or above 3,900 units by the end of Q2 2026.
Disproves:Installed base reported below 3,800 units by the end of Q2 2026.
Why it matters: Recurring revenue is crucial for Cytek's growth strategy. An increase signals strong demand.
Confirms:Recurring revenue is more than 35% of total revenue.
Disproves:Recurring revenue is less than 35% of total revenue.
Why it matters: Changes in leadership can change sales strategies. This can affect revenue growth.
Confirms one read:Sales performance improves in Q2 2026 compared to Q1 2026.
Confirms the other:Sales performance declines in Q2 2026 compared to Q1 2026.
and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.